Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

diluted, compared to a net income of $0.29 per share, basic, and $0.25 per share, diluted, for the same period in 2007. Net income per share for the year ended December 31, 2008 was $0.95 per share, basic, and $0.83 per share, diluted, compared to net income of $1.37 per share, basic, and $1.21 per share, diluted, for the same period in 2007.

The primary drivers of the decrease in net income for the fourth quarter and year ended December 31, 2008 were the increase in R&D, SG&A and intangible amortization expenses, and lower interest income offset by the lower tax expense. Additionally, in the fourth quarter of 2008 we had a $2.3 million charge to write down to fair value our previous corporate headquarters which is currently held for sale.

Operating Highlights

During the three months and year ended December 31, 2008, net sales increased 4.9 percent and 14.0 percent, respectively, compared to the same periods in 2007.

The cost of sales for the three months and year ended December 31, 2008 increased $0.1 million and remained consistent, respectively, as compared to the same periods in 2007. For the three months and year ended December 31, 2008 the cost of sales was $2.1 million and $8.9 million, respectively, compared to $2.0 million and $8.9, respectively, for the same period in 2007.

Investment in our product pipeline and the company continued to grow as research and development (R&D) and selling, general and administrative (SG&A) expenses in the fourth quarter and year ended December 31, 2008 were $43.6 million and $131.7 million, respectively compared to $25.2 million and $72.9 million for the fourth quarter and year ended December 31, 2007, respectively. The quarter increases were due primarily to our investments in our infrastructure related to our development programs, costs to support the Cinryze open label trial and launch related costs, an
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 21, 2014 , ...   Mariano Rodríguez es elegid vicepresidente senior ... KLOX está en marcha para comenzar de forma rápida ... heridas de reciente aprobación en Europa   , ... complace al anunciar los siguientes nombramientos: Todd ...
(Date:11/21/2014)... The California Healthcare Institute ... representing leading California academic institutions, biotechnology, medical device, ... today released a report revealing that California ... The trend shows a 4 percent increase between ... Industry Report indicates that, while biopharmaceutical and ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... month periods ended September 30, 2014.  Biorem,s complete 2014 third quarter ... ). Financial Summary:Three-months ended September 30, , ... share data) , 2014 , 2013 ... , 5,281 , 6,715 , ...
Breaking Biology Technology:KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... ... The 2nd Algae World Europe conference in Brussels addresses ... engineering, marketing and financial aspects of the algae value chain. Panel ... biofuels and high-value co-products like pharmaceuticals, nutraceuticals, cosmetics, aquaculture feed, bioplastics, ...
... , , ... Ltd, a specialty,biopharmaceutical company focused on allergy, today announced ... in a,recently completed phase II clinical trial. Ragweed allergy ... of the population.,Circassia,s latest clinical results follow two earlier ...
... , , , , ... 3SBio Inc. (Nasdaq:, SSRX ), a leading biotechnology company ... in China ,today announced that it has submitted ... to the Chinese State Food and Drug Administration (SFDA).,NuPIAO ...
Cached Biology Technology:2nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 22nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 3Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine 2Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine 33SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial 23SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial 3
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
(Date:11/10/2014)... store shelves in early 2010, and people have used ... can be tossed into a washing machine without ever ... convenience, though, has come with risks for young children. ... Hospital found that from 2012 through 2013, U.S. poison ... 6 years of age swallowing, inhaling, or otherwise being ...
(Date:11/6/2014)... A groundbreaking paper from a team of Florida State ... how plants could adapt to and survive environmental swings ... in the latest issue of the journal The ... complex of DNA and proteins) is organized in a ... some genes are turned on and others are turned ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2
... important new study assessing the demographic impact of the ... 60 prehistoric American cemeteries to prove that the invention ... birth rate. , Discussing the shifts in the ... in Europe at the end of the Stone Age, ...
... tools and cryo-electron microscopes, researchers at Baylor College of Medicine ... and, in doing so, opened the door to a better ... animals. , In a report that appears in and on ... Dr. Wah Chiu, professor in the BCM department of biochemistry ...
... Bioinformatics Institute (VBI) at Virginia Tech, Colorado State ... a new method to determine gene function on ... brassicicola. This destructive fungus causes black spot disease, ... important crops as canola, cabbage, and broccoli. ...
Cached Biology News:Unraveling the viral mechanism 2New method enables gene disruption in destructive fungal pathogen 2
... The four-bay DNA Engine Tetrad 2 ... interchangeable Alpha units (sample-holder, heat-pump assemblies), ... of vessels. A Pentium-class computer drives ... current block, sample, and lid temperatures. ...
4',6-Diamidino-2-phenylindole, dihydrochloride (DAPI)...
... has been developed with the drug discovery ... flexibility, sensitivity and performance, Safire is the ... assay development and high throughput screening. Safire ... system that offers a range of high ...
... cm, is used for vertical slab gel electrophoresis ... The cell is supplied without spacers and combs. ... gaskets, lower buffer chamber, lid with cables, 2 ... buffer dam, casting stand with gaskets, leveling bubble, ...
Biology Products: